Spots Global Cancer Trial Database for Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Official Title: An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Study ID: NCT03333915
Interventions
Study Description
Brief Summary: This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary peritoneal cancer) and triple negative breast cancer in phase I, and to evaluate the efficacy and safety of pamiparib in Chinese participants with recurrent epithelial ovarian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline breast cancer susceptibility gene 1/gene 2 (BRCA1/2) mutation in phase II.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
Peking University People Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
The First Bethune Hospital of Jilin University, Jilin, Changchun, China
Chongqing Cancer Hospital, Chongqing, Chongqing, China
SUN YAT-SEN memorial hospital,SUN YAT-SEN University, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
Jilin Cancer Hospital, Changchun, Jilin, China
The second Hospital of Jilin University, Changchun, Jilin, China
The First Hospital of Dalian Medical University, Dalian, Liaoning, China
The First Affiliated Hospital of Xian Jiaotong University, Dalian, Liaoning, China
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
QILU Hospital of Shandong University, Jinan, Shandong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
West China Hospital Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer institute & Hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Study Director
Affiliation: BeiGene
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
